Innovative personalised immunotherapy approved for multiple myeloma
European Pharmaceutical Review
APRIL 8, 2024
The first BCMA-targeted CAR-T cell therapy for second-line treatment of multiple myeloma has been approved by the US Food and Drug Administration (FDA). Janssen), a Johnson & Johnson company in December 2017.
Let's personalize your content